

Baxter International Inc.
Key Product Line Sales
Period Ending June 30, 2004
(unaudited)

(\$ in millions)	Q2 2004	Q2 2003	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2004	YTD 2003	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
Recombinants	\$320	\$253	26%	21%	\$612	\$497	23%	16%
Plasma Proteins ¹	267	230	16%	12%	505	459	10%	5%
Antibody Therapy	90	71	26%	24%	170	138	23%	18%
Transfusion Therapies	136	136	0%	(4%)	276	270	2%	(3%)
Other ²	80	83	(3%)	(15%)	140	149	(5%)	(17%)
Total BioScience	\$893	\$773	16%	11%	\$1,703	\$1,513	13%	6%
Medication Delivery								
IV Therapies ³	\$288	\$271	6%	2%	\$570	\$519	10%	4%
Drug Delivery	188	168	12%	10%	362	329	10%	8%
Electronic Infusion Systems	213	191	11%	9%	386	357	8%	5%
Anesthesia	206	201	2%	2%	397	382	4%	3%
Other ⁴	111	107	6%	0%	220	201	10%	(1%)
Total Medication Delivery ⁵	\$1,006	\$938	7%	4%	\$1,935	\$1,788	8%	4%
Renal								
PD Therapy	\$357	\$337	6%	1%	\$702	\$638	10%	4%
HD Therapy	118	111	6%	1%	239	214	12%	5%
Other	5	4	0%	(6%)	9	7	22%	25%
Total Renal	\$480	\$452	6%	1%	\$950	\$859	10%	4%
TOTAL BAXTER	\$2,379	\$2,163	10%	6%	\$4,588	\$4,160	10%	5%

¹ Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, biosurgery (Tisseel) and other plasma-based products.

² Principally includes vaccines and non-plasma-based biosurgery products (FioSeal & CoSeal).

³ Principally includes intravenous solutions and nutritional products.

⁴ Principally includes oncology and other hospital-distributed products.

⁵ Sales of pain management products, which were previously included in Anesthesia, are now reported in Electronic Infusion Systems or Other, depending on the product. All prior has been reclassified to reflect this change.

As noted in the press release, the company plans to restate its financial results back to 2001. The prior quarter and/or year-to-date results shown above do not yet reflect the restatement or the effects thereof and should be read accordingly.